Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
25 01 2021
Historique:
received: 02 12 2020
revised: 19 01 2021
accepted: 20 01 2021
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 3 3 2021
Statut: epublish

Résumé

Molecular investigation of primary HIV infections (PHI) is crucial to describe current dynamics of HIV transmission. Aim of the study was to investigate HIV transmission clusters (TC) in PHI referred during the years 2013-2020 to the National Institute for Infectious Diseases in Rome (INMI), that is the Lazio regional AIDS reference centre, and factors possibly associated with inclusion in TC. These were identified by phylogenetic analysis, based on population sequencing of

Identifiants

pubmed: 33503987
pii: v13020176
doi: 10.3390/v13020176
pmc: PMC7911907
pii:
doi:

Substances chimiques

RNA, Viral 0
env Gene Products, Human Immunodeficiency Virus 0
pol Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Infect Genet Evol. 2016 Jun;40:91-97
pubmed: 26921800
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
PLoS One. 2015 May 26;10(5):e0125699
pubmed: 26010948
J Infect Dis. 2007 Apr 1;195(7):951-9
pubmed: 17330784
PLoS One. 2009;4(3):e4724
pubmed: 19266092
Infect Genet Evol. 2016 Sep;43:329-37
pubmed: 27282472
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
AIDS. 2001 May 4;15(7):837-45
pubmed: 11399956
Bioinformatics. 2003 Aug 12;19(12):1572-4
pubmed: 12912839
Sci Rep. 2018 Jan 23;8(1):1404
pubmed: 29362487
Mol Biol Evol. 2005 May;22(5):1185-92
pubmed: 15703244
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Clin Infect Dis. 2014 Apr;58(8):1156-64
pubmed: 24429430
AIDS. 2005 Mar 4;19(4):449-50
pubmed: 15750402
J Virol Methods. 2014 Aug;204:31-7
pubmed: 24731928
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Mol Biol Evol. 1984 Apr;1(3):269-85
pubmed: 6599968
AIDS Res Hum Retroviruses. 2018 Oct;34(10):879-888
pubmed: 30027754
Sex Transm Infect. 2019 Dec;95(8):619-625
pubmed: 31076456
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
AIDS. 2013 Apr 24;27(7):1045-57
pubmed: 23902920
J Antimicrob Chemother. 2015 Jul;70(7):2084-9
pubmed: 25885327
J Antimicrob Chemother. 2014 Nov;69(11):3085-94
pubmed: 25015667
AIDS. 2019 Mar 15;33(4):691-699
pubmed: 30585843
Sci Rep. 2016 Sep 19;6:32251
pubmed: 27642070
J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):424-8
pubmed: 12640201
AIDS. 2020 Nov 15;34(14):2037-2044
pubmed: 32773483
PLoS One. 2014 Jul 08;9(7):e101738
pubmed: 25003369
BMC Evol Biol. 2007 Nov 08;7:214
pubmed: 17996036
J Infect Dis. 2008 Sep 1;198(5):687-93
pubmed: 18662132
Clin Infect Dis. 2012 Oct;55(8):1135-43
pubmed: 22784872
AIDS Res Hum Retroviruses. 2013 Feb;29(2):343-9
pubmed: 22860694
AIDS. 2011 Mar 13;25(5):611-7
pubmed: 21160417
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):356-363
pubmed: 27400403
Retrovirology. 2017 Feb 21;14(1):15
pubmed: 28222757
Mol Biol Evol. 2001 Jun;18(6):1001-13
pubmed: 11371589
Nat Biotechnol. 2007 Dec;25(12):1407-10
pubmed: 18066037
AIDS. 2005 Jan 3;19(1):85-90
pubmed: 15627037
J Clin Microbiol. 2017 Sep;55(9):2827-2837
pubmed: 28701420
J Antimicrob Chemother. 2017 Oct 1;72(10):2837-2845
pubmed: 29091206
AIDS. 2018 Oct 23;32(16):2373-2381
pubmed: 30096068
J Antimicrob Chemother. 2011 Nov;66(11):2615-23
pubmed: 21890537
J Infect Dis. 2011 Nov;204(9):1463-9
pubmed: 21921202
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
N Engl J Med. 2011 May 19;364(20):1943-54
pubmed: 21591946
New Microbiol. 2017 Apr;40(2):86-98
pubmed: 28513816
AIDS. 2013 Nov 13;27(17):2665-78
pubmed: 23842129
Curr Opin HIV AIDS. 2010 Jul;5(4):277-82
pubmed: 20543601
Sci Rep. 2020 Feb 6;10(1):1989
pubmed: 32029767

Auteurs

Lavinia Fabeni (L)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Gabriella Rozera (G)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Giulia Berno (G)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Emanuela Giombini (E)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Caterina Gori (C)

Laboratory of Clinical Pathology, San Camillo-Forlanini Hospital, 00149 Rome, Italy.

Nicoletta Orchi (N)

AIDS Referral Center, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Gabriella De Carli (G)

AIDS Referral Center, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Silvia Pittalis (S)

AIDS Referral Center, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Vincenzo Puro (V)

AIDS Referral Center, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Carmela Pinnetti (C)

HIV/AIDS Clinical Department, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Annalisa Mondi (A)

HIV/AIDS Clinical Department, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Marta Camici (M)

HIV/AIDS Clinical Department, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Maria Maddalena Plazzi (MM)

HIV/AIDS Clinical Department, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Andrea Antinori (A)

HIV/AIDS Clinical Department, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Maria Rosaria Capobianchi (MR)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Isabella Abbate (I)

Virology and Biosafety Laboratories Unit, "Lazzaro Spallanzani"-IRCCS, National Institute for Infectious Diseases, 00149 Rome, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH